MCID: NRM001
MIFTS: 67

Neuromyelitis Optica

Categories: Rare diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Neuromyelitis Optica

MalaCards integrated aliases for Neuromyelitis Optica:

Name: Neuromyelitis Optica 37 12 49 24 50 55 36 51 41 14 69
Devic Syndrome 72 49 24
Devic Disease 49 24 55
Devic's Syndrome 12 50
Devic's Disease 12 24
Opticospinal Multiple Sclerosis 69
Devic's Neuromyelitis Optica 49
Devic Neuromyelitis Optica 24
Nmo Spectrum Disorder 49
Optic-Spinal Ms 24
Opticospinal Ms 24
Nmo 49

Characteristics:

Orphanet epidemiological data:

55
neuromyelitis optica
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:8869
ICD10 32 G36.0
ICD9CM 34 341.0
MeSH 41 D009471
NCIt 46 C84934
SNOMED-CT 64 25044007
Orphanet 55 ORPHA71211
MESH via Orphanet 42 D009471
UMLS via Orphanet 70 C0027873
ICD10 via Orphanet 33 G36.0
KEGG 36 H01491

Summaries for Neuromyelitis Optica

NINDS : 50 Neuromyelitis optica (NMO) is an autoimmune disease of the central nervous system (CNS) that predominantly affects the optic nerves and spinal cord. It is sometimes also referred to as NMO spectrum disorder.In NMO, the body's immune system mistakenly attacks healthy cells and proteins in the body, must often those in the spinal cord and eyes. Individuals with NMO develop optic neuritis, which caused pain in the eye and vision loss. Individuals also develop transverse myelitis, which causes weakness or paralysis of arms and legs,and numbness, along with loss of bladder and bowel control Magnetic resonance imaging of the spine often shows an abnormality that extends over  long segments of the spinal cord. Individuals may also develop episodes of severe nausea and vomiting, with hiccups from involvement of a part of the brain that ocntrols vomiting The disease is caused by abnormal autoantibodies that bind to a protein called aquaporin-4. Binding of the aquaporin-4 antibody activates other components of the immune system, causing inflammation and damage to these cells. This also results in the brain and spinal cord the loss of myelin, the fatty substance that acts as insulation around nerve fibers and helps nerve signals move from cell to cell.  NMO is different from multiple sclerosis (MS). Attacks are usually more severe in NMO than in MS, and NMO is treated differently than MS. Most individuals with NMO experience clusters of attacks days to months or years apart, followed by partial recovery during periods of remission. Women are more often affected by NMO than men. African Americans are at greater risk of the disease than are Caucasians. The onset of NMO varies from childhood to adulthood, with two peaks, one in childhood and the other in adults in their 40s.

MalaCards based summary : Neuromyelitis Optica, also known as devic syndrome, is related to transverse myelitis and neuritis, and has symptoms including visual loss, sensory impairment and autoimmune antibody positivity. An important gene associated with Neuromyelitis Optica is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Allograft rejection and Th17 cell differentiation. The drugs Mitoxantrone and Mycophenolate mofetil have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, spinal cord and brain, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A central nervous system disease characterized by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis).

Genetics Home Reference : 24 Neuromyelitis optica is an autoimmune disorder that affects the nerves of the eyes and the central nervous system, which includes the brain and spinal cord. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In neuromyelitis optica, the autoimmune attack causes inflammation of the nerves, and the resulting damage leads to the signs and symptoms of the condition.

NIH Rare Diseases : 49 Neuromyelitis optica is an autoimmune disease that affects the spinal cord and optic nerves (nerves that carry visual messages to and from the brain). In neuromyelitis optica, the body's immune system mistakenly attacks healthy cells and a substance called myelin in the spinal cord and eyes. Symptoms may begin in childhood or adulthood. Spinal cord involvement results in transverse myelitis, which may cause pain, paralysis and abnormal sensations in the spine and limbs. Bladder and bowel problems may also develop. Symptoms from optic nerve involvement include eye pain and vision loss from optic neuritis. Other symptoms of neuromyelitis optica may include episodes of nausea, vomiting, and hiccups. Some people have episodes of symptoms months or years apart (the relapsing form), while others have a single episode lasting several months (the monophasic form). In either form, people with neuromyelitis optica often develop permanent muscle weakness and vision loss. The cause of the immune system dysfunction leading to neuromyelitis optica is not known. It usually occurs in only one person in a family. There is no cure, but there are therapies to reduce symptoms during episodes and prevent relapses. Last updated: 11/6/2017

Wikipedia : 72 Neuromyelitis optica (NMO), also known as Devic\'s disease or Devic\'s syndrome, is a heterogeneous... more...

Related Diseases for Neuromyelitis Optica

Diseases in the Neuromyelitis Optica family:

Neuromyelitis Optica Spectrum Disorder

Diseases related to Neuromyelitis Optica via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 189)
# Related Disease Score Top Affiliating Genes
1 transverse myelitis 32.3 AQP4 IL17A IL6 MBP
2 neuritis 31.3 AQP4 MBP MOG
3 optic neuritis 31.1 AQP4 HLA-DRB1 MBP MOG
4 encephalitis 30.7 AQP4 GFAP MOG
5 acute transverse myelitis 30.7 AQP4 IL6
6 panencephalitis, subacute sclerosing 30.3 MBP MOG
7 demyelinating disease 30.1 AQP4 IL17A MBP MOG
8 myelitis 29.9 AQP4 HLA-DPB1 IL17A IL6 MBP MOG
9 radiculopathy 29.9 IL17A IL6
10 connective tissue disease 29.8 HLA-DPB1 HLA-DRB1 IL6 TNFSF13B
11 multiple sclerosis 29.8 AQP4 GFAP HLA-DRB1 IL17A IL6 MBP
12 internuclear ophthalmoplegia 29.6 AQP4 HCRT MBP MOG
13 acute disseminated encephalomyelitis 29.5 AQP4 HCRT HLA-DRB1 MBP MOG
14 relapsing-remitting multiple sclerosis 29.5 AQP4 IL17A IL6 MBP MOG
15 systemic lupus erythematosus 29.4 HLA-DPB1 HLA-DRB1 IL17A IL6 TNFSF13B
16 autoimmune disease 29.0 HLA-DRB1 IL17A IL6 MBP MOG TNFSF13B
17 narcolepsy 28.9 AQP4 HCRT HLA-DPB1 HLA-DRB1 MOG
18 neuromyelitis optica spectrum disorder 12.5
19 marburg acute multiple sclerosis 11.2
20 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.5
21 obstructive hydrocephalus 10.5 AQP4 GFAP
22 chiari malformation 10.4 GFAP MBP
23 retinitis 10.4
24 anca-associated vasculitis 10.4 HLA-DRB1 IL6
25 allergic encephalomyelitis 10.4 MBP MOG
26 pediatric multiple sclerosis 10.4 HLA-DRB1 MOG
27 rheumatoid arthritis, systemic juvenile 10.4 HLA-DRB1 IL6
28 microscopic colitis 10.3 HLA-DRB1 IL6
29 inappropriate adh syndrome 10.3 AQP1 AQP4
30 leukoencephalopathy, hereditary diffuse, with spheroids 10.3 GFAP SLC1A2
31 dysferlinopathy 10.3 AQP1 AQP4
32 intracranial hypertension, idiopathic 10.3 AQP1 AQP4
33 ascaris lumbricoides infection 10.3 IL6 TNFSF13B
34 transient arthritis 10.3 IL6 MBP
35 neuroretinitis 10.3 AQP4 MOG
36 wernicke encephalopathy 10.3 GFAP SLC1A2
37 episodic pain syndrome, familial, 1 10.3
38 cervicitis 10.3
39 cerebritis 10.3
40 beryllium disease 10.3 HLA-DPB1 HLA-DRB1
41 berylliosis 10.3 HLA-DPB1 HLA-DRB1
42 spinal cord injury 10.3 AQP4 GFAP IL6
43 chronic beryllium disease 10.3 HLA-DPB1 HLA-DRB1
44 balo concentric sclerosis 10.3 AQP4 MBP MOG
45 brain injury 10.3 GFAP IL6 MBP
46 spinal cord disease 10.3 AQP4 MBP MOG
47 encephalomalacia 10.3 IL6 MBP
48 osteonecrosis of the jaw 10.2 HLA-DRB1 IL17A
49 myasthenia gravis 10.2
50 neuropathy 10.2

Graphical network of the top 20 diseases related to Neuromyelitis Optica:



Diseases related to Neuromyelitis Optica

Symptoms & Phenotypes for Neuromyelitis Optica

Human phenotypes related to Neuromyelitis Optica:

55 31 (show all 30)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 visual loss 55 31 occasional (7.5%) Very frequent (99-80%) HP:0000572
2 sensory impairment 55 31 hallmark (90%) Very frequent (99-80%) HP:0003474
3 autoimmune antibody positivity 55 31 frequent (33%) Very frequent (99-80%) HP:0030057
4 functional abnormality of the bladder 55 Very frequent (99-80%)
5 neuronal loss in central nervous system 55 Very frequent (99-80%)
6 paraplegia 55 Very frequent (99-80%)
7 peripheral demyelination 55 Very frequent (99-80%)
8 myelitis 55 Very frequent (99-80%)
9 optic neuritis 55 Very frequent (99-80%)
10 ocular pain 55 Very frequent (99-80%)
11 abnormality of brain morphology 55 Frequent (79-30%)
12 nausea 55 Occasional (29-5%)
13 respiratory failure 55 Occasional (29-5%)
14 csf pleocytosis 55 Occasional (29-5%)
15 recurrent singultus 55 Occasional (29-5%)
16 anxiety 31 occasional (7.5%) HP:0000739
17 hyperthyroidism 31 occasional (7.5%) HP:0000836
18 seizures 31 occasional (7.5%) HP:0001250
19 nausea and vomiting 31 occasional (7.5%) HP:0002017
20 hyperproteinemia 31 frequent (33%) HP:0002152
21 hyperkalemia 31 occasional (7.5%) HP:0002153
22 tetraparesis 31 frequent (33%) HP:0002273
23 dysautonomia 31 hallmark (90%) HP:0002459
24 increased intracranial pressure 31 occasional (7.5%) HP:0002516
25 abnormality of the cerebrospinal fluid 31 occasional (7.5%) HP:0002921
26 hypochloremia 31 occasional (7.5%) HP:0003113
27 abnormality of the urinary system physiology 31 frequent (33%) HP:0011277
28 abnormal leukocyte count 31 frequent (33%) HP:0011893
29 cognitive impairment 31 occasional (7.5%) HP:0100543
30 spinal cord lesion 31 frequent (33%) HP:0100561

MGI Mouse Phenotypes related to Neuromyelitis Optica:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 AQP1 AQP4 GFAP HCRT IL6 MBP
2 growth/size/body region MP:0005378 9.97 AQP1 AQP4 GFAP HCRT IL17A IL6
3 hematopoietic system MP:0005397 9.86 TNFSF13B AQP1 AQP4 CD59 IL17A IL6
4 homeostasis/metabolism MP:0005376 9.81 AQP1 AQP4 CD59 GFAP HCRT IL17A
5 nervous system MP:0003631 9.56 AQP1 AQP4 GFAP HCRT IL6 MBP
6 vision/eye MP:0005391 9.1 GFAP IL6 MBP MOG AQP1 AQP4

Drugs & Therapeutics for Neuromyelitis Optica

Drugs for Neuromyelitis Optica (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
2
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
3
Mycophenolic acid Approved Phase 4 24280-93-1 446541
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5 Analgesics Phase 4
6 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1
7 Topoisomerase Inhibitors Phase 4
8 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1
9 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1
10 glucocorticoids Phase 4,Phase 3,Phase 1
11 Hormone Antagonists Phase 4,Phase 3,Phase 1
12 Hormones Phase 4,Phase 3,Phase 1
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1
14 Anti-Bacterial Agents Phase 4
15 Antibiotics, Antitubercular Phase 4
16 Anti-Infective Agents Phase 4
17 Antitubercular Agents Phase 4
18
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 83-43-2 6741
19
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 50-24-8 5755
20
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
21
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696
22 Antiemetics Phase 3,Phase 1
23 Autonomic Agents Phase 3,Phase 1
24 Gastrointestinal Agents Phase 3,Phase 1
25 Methylprednisolone acetate Phase 3,Phase 1,Phase 2
26 Methylprednisolone Hemisuccinate Phase 3,Phase 1,Phase 2
27 Neuroprotective Agents Phase 3,Phase 1
28 Prednisolone acetate Phase 3,Phase 1,Phase 2
29 Prednisolone hemisuccinate Phase 3,Phase 1,Phase 2
30 Prednisolone phosphate Phase 3,Phase 1,Phase 2
31 Protective Agents Phase 3,Phase 1
32 Antimetabolites Phase 2, Phase 3
33 Antimetabolites, Antineoplastic Phase 2, Phase 3
34 Antirheumatic Agents Phase 2, Phase 3, Phase 1
35 Immunosuppressive Agents Phase 2, Phase 3, Phase 1
36 Antibodies Phase 3,Phase 2,Phase 1
37 Immunoglobulins Phase 3,Phase 2,Phase 1
38 gamma-Globulins Phase 3,Phase 2
39 Immunoglobulins, Intravenous Phase 3,Phase 2
40 Rho(D) Immune Globulin Phase 3,Phase 2
41 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
42
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 657311 5754
43
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
44
Cetirizine Approved Phase 1, Phase 2 83881-51-0 2678
45
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6, 75614-87-8 774
46
4-Aminopyridine Approved Phase 2 504-24-5 1727
47
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
48
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
49
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
50
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743

Interventional clinical trials:

(show all 46)

# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
2 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
3 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Enrolling by invitation NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
4 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
5 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
6 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Recruiting NCT03330418 Phase 3
7 Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Recruiting NCT03350633 Phase 2, Phase 3 Tocilizumab Injection;Azathioprine
8 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02200770 Phase 2, Phase 3
9 Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD Recruiting NCT02028884 Phase 3 satralizumab (SA237);Placebo
10 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Active, not recruiting NCT01892345 Phase 3 Eculizumab
11 Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD Active, not recruiting NCT02073279 Phase 3 satralizumab (SA237);Placebo
12 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Enrolling by invitation NCT02003144 Phase 3
13 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
14 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
15 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Unknown status NCT02249676 Phase 2
16 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2 cetirizine
17 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
18 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2 NPB-01
19 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
20 Scrambler Trial for Pain in NMOSD Recruiting NCT03452176 Phase 2
21 Hematopoietic Stem Cell Transplant in Devic's Disease Recruiting NCT00787722 Phase 1, Phase 2
22 Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder Active, not recruiting NCT02893111 Phase 2 Bortezomib
23 A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Active, not recruiting NCT03062579 Phase 1, Phase 2 Tocilizumab
24 Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Terminated NCT01339455 Phase 1, Phase 2
25 Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Unknown status NCT02087813 Phase 1 Alpha1-antitrypsin;methylprednisolone
26 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Completed NCT01759602 Phase 1 C1-esterase inhibitor (Cinryze)
27 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
28 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Completed NCT01777412 Phase 1 Bevacizumab
29 Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Recruiting NCT02283671 Phase 1
30 Central Pain Study for ABX-1431 Recruiting NCT03138421 Phase 1 ABX-1431 HCl;Placebo
31 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
32 Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct Unknown status NCT01024985
33 Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis Completed NCT03122873
34 Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02836327
35 The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) Recruiting NCT02850705
36 The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders Recruiting NCT01623076
37 The French Multiple Sclerosis Registry Recruiting NCT02889965
38 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Recruiting NCT02886377
39 Optical Coherence Tomography and Optic Neuritis (OCTON) Recruiting NCT02573792
40 Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients Recruiting NCT02789670
41 Stem Cell Ophthalmology Treatment Study II Recruiting NCT03011541
42 Maintenance Plasma Exchange for Neuromyelitis Optica Active, not recruiting NCT01500681
43 Biobank For MS And Other Demyelinating Diseases Active, not recruiting NCT00445367
44 Pathologic-MRI Findings in Atypical IIDD Active, not recruiting NCT03121105
45 Stem Cell Ophthalmology Treatment Study Enrolling by invitation NCT01920867
46 Optic Neuritis Differential Diagnosis Study Not yet recruiting NCT03370965

Search NIH Clinical Center for Neuromyelitis Optica

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Neuromyelitis Optica cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: neuromyelitis optica

Genetic Tests for Neuromyelitis Optica

Anatomical Context for Neuromyelitis Optica

MalaCards organs/tissues related to Neuromyelitis Optica:

38
Spinal Cord, Brain, Eye, T Cells, B Cells, Neutrophil, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Neuromyelitis Optica:
# Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Neuromyelitis Optica

Articles related to Neuromyelitis Optica:

(show top 50) (show all 950)
# Title Authors Year
1
Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental inA vitro and rat models of neuromyelitis optica. ( 29428821 )
2018
2
Development of Neuromyelitis Optica Spectrum Disorder and Spinal Arachnoid Cysts in a Patient With Intractable Epilepsy. ( 29379967 )
2018
3
Low body mass index can be associated with the risk and poor outcomes of neuromyelitis optica with aquaporin-4 immunoglobulin G in women. ( 29371414 )
2018
4
Worldwide prevalence of neuromyelitis optica spectrum disorders. ( 29436488 )
2018
5
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms? ( 29159372 )
2018
6
Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. ( 29361915 )
2018
7
Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients. ( 29367170 )
2018
8
Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization. ( 29297041 )
2018
9
Teaching NeuroImages: Leber hereditary optic neuropathy masquerading as neuromyelitis optica. ( 29284658 )
2018
10
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms? ( 29159373 )
2018
11
Neuromyelitis optica and neuromyelitis optica like spectrum disorders: Is it not the time to change the criteria? ( 29414289 )
2018
12
Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder. ( 29406915 )
2018
13
Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. ( 29359475 )
2018
14
MRI Features of Aquaporin-4 Antibody-Positive Longitudinally Extensive Transverse Myelitis: Insights into the Diagnosis of Neuromyelitis Optica Spectrum Disorders. ( 29449281 )
2018
15
Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder. ( 29249386 )
2018
16
Retinal ganglion cell-inner plexiform and nerve fiber layers in neuromyelitis optica. ( 29375997 )
2018
17
Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review. ( 29388807 )
2018
18
Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders. ( 29414283 )
2018
19
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms?-Reply. ( 29159366 )
2018
20
Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. ( 29414288 )
2018
21
Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder. ( 29414297 )
2018
22
The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder. ( 29349658 )
2018
23
A Rare Presentation of Neuromyelitis Optica Spectrum Disorders. ( 29434480 )
2018
24
Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica. ( 29447335 )
2018
25
The evolving mystery of why skeletal muscle is spared in seropositive neuromyelitis optica. ( 29363875 )
2018
26
Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. ( 29406904 )
2018
27
Retinal segmented layers with strong aquaporin-4 expression suffered more injuries in neuromyelitis optica spectrum disorders compared with optic neuritis with aquaporin-4 antibody seronegativity detected by optical coherence tomography. ( 28057643 )
2017
28
Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis. ( 28009104 )
2017
29
Orbital Ectopic Lymphoid Follicles with Germinal Centers in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders. ( 29387055 )
2017
30
Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence. ( 28458709 )
2017
31
Anti-N-methyl-D-aspartate receptor(NMDAR) antibody encephalitis presents in atypical types and coexists with neuromyelitis optica spectrum disorder or neurosyphilis. ( 28056870 )
2017
32
Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders. ( 28080220 )
2017
33
Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. ( 28451627 )
2017
34
Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. ( 28920766 )
2017
35
Pregnancy in neuromyelitis optica spectrum disorder: A multicenter study from South China. ( 28017203 )
2017
36
Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest. ( 28483993 )
2017
37
Reply to letter to the editor: Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder by Pitarokoili and Gold. ( 28747150 )
2017
38
Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important. ( 28080211 )
2017
39
Can Wernekink commissure syndrome and wall-eyed bilateral internuclear ophthalmoplegia be ascribed to neuromyelitis optica spectrum disorder? ( 28681309 )
2017
40
Acute-Onset Severe Occipital Neuralgia Associated With High Cervical Lesion in Patients With Neuromyelitis Optica Spectrum Disorder. ( 28699327 )
2017
41
Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder. ( 28725551 )
2017
42
Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: Two new cases. ( 28580873 )
2017
43
Pruritus may be a common symptom related to neuromyelitis optica spectrum disorders. ( 28427688 )
2017
44
Myointimal Hyperplasia in a Patient with Neuromyelitis Optica (Devic's Disease) after the Creation of an Arteriovenous Graft. ( 29422845 )
2017
45
Treatment for paraneoplastic neuromyelitis optica spectrum disorder (NMOsd): Probable effects of tocilizumab for both cancer and NMOsd. ( 29353735 )
2017
46
Author response: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest. ( 28483994 )
2017
47
Neuromyelitis Optica Spectrum Disorders. ( 28391784 )
2017
48
Reply concerning Statistical Comments on "Cytokine and Chemokine Profiles in Patients with Neuromyelitis Optica Spectrum Disorder". ( 28854434 )
2017
49
Convergence spasm due to aquaporin-positive neuromyelitis optica spectrum disorder. ( 29260017 )
2017
50
MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease? ( 29194504 )
2017

Variations for Neuromyelitis Optica

Expression for Neuromyelitis Optica

Search GEO for disease gene expression data for Neuromyelitis Optica.

Pathways for Neuromyelitis Optica

GO Terms for Neuromyelitis Optica

Cellular components related to Neuromyelitis Optica according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.16 HLA-DPB1 HLA-DRB1
2 MHC class II protein complex GO:0042613 8.96 HLA-DPB1 HLA-DRB1
3 ER to Golgi transport vesicle membrane GO:0012507 8.8 CD59 HLA-DPB1 HLA-DRB1

Biological processes related to Neuromyelitis Optica according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.73 HCRT IL17A IL6 TNFSF13B
2 renal water homeostasis GO:0003091 9.46 AQP1 AQP4
3 positive regulation of interleukin-6 secretion GO:2000778 9.4 IL17A MBP
4 water transport GO:0006833 9.37 AQP1 AQP4
5 T cell costimulation GO:0031295 9.33 HLA-DPB1 HLA-DRB1 TNFSF13B
6 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.32 HLA-DPB1 HLA-DRB1
7 multicellular organismal water homeostasis GO:0050891 9.26 AQP1 AQP4
8 positive regulation of T cell proliferation GO:0042102 9.13 HLA-DPB1 IL6 TNFSF13B
9 immune response GO:0006955 9.1 HLA-DPB1 HLA-DRB1 IL17A IL6 MBP TNFSF13B

Molecular functions related to Neuromyelitis Optica according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 channel activity GO:0015267 9.26 AQP1 AQP4
2 peptide antigen binding GO:0042605 9.16 HLA-DPB1 HLA-DRB1
3 water channel activity GO:0015250 8.96 AQP1 AQP4
4 water transmembrane transporter activity GO:0005372 8.62 AQP1 AQP4

Sources for Neuromyelitis Optica

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....